1.
Juliana Velez Lujan, Paula A. Lengerke-Diaz, Chaja Jacobs, Eider F. Moreno-Cortes, Cesar A. Ramirez-Segura, Michael Y. Choi, Colin McCarthy, Alaina Heinen, Thomas J. Kipps, Januario E. Castro. Ibrutinib reduces obinutuzumab infusion-related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels. haematol [Internet]. 2020Jan.1 [cited 2021Dec.1];105(1):e22-e25. Available from: https://haematologica.org/article/view/9499